There is nothing really announce in this after hours PR. I’d be more upset to this Premarket. The only thing to take away from this is that it confirms that there is a path for regulatory approval which 90+% of us already believed. Other than that there is not a lot of take aways. Nadar said big news by Friday , so he PR on time but without much to go on. It’s very possible they didn’t share the recommendation in the PR because then all is in FDA court. I will be ticked off if we’re told Tuesday that they recommended trial continue to 390 and that’s it. But they are going to have a slide show hopefully they decided to unblind the data and will be going for EUA from FDA and from other countries. Wait is on now